204 related articles for article (PubMed ID: 33519456)
1. Physiologically-Based Pharmacokinetic-Pharmacodynamics Model Characterizing CYP2C19 Polymorphisms to Predict Clopidogrel Pharmacokinetics and Its Anti-Platelet Aggregation Effect Following Oral Administration to Coronary Artery Disease Patients With or Without Diabetes.
Xu RJ; Kong WM; An XF; Zou JJ; Liu L; Liu XD
Front Pharmacol; 2020; 11():593982. PubMed ID: 33519456
[No Abstract] [Full Text] [Related]
2. Enhanced Platelet Response to Clopidogrel in Zucker Diabetic Fatty Rats due to Impaired Clopidogrel Inactivation by Carboxylesterase 1 and Increased Exposure to Active Metabolite.
Yao H; Bai R; Ren T; Wang Y; Gu J; Guo Y
Drug Metab Dispos; 2019 Aug; 47(8):794-801. PubMed ID: 31092394
[TBL] [Abstract][Full Text] [Related]
3. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease.
Angiolillo DJ; Jakubowski JA; Ferreiro JL; Tello-Montoliu A; Rollini F; Franchi F; Ueno M; Darlington A; Desai B; Moser BA; Sugidachi A; Guzman LA; Bass TA
J Am Coll Cardiol; 2014 Sep; 64(10):1005-14. PubMed ID: 25190236
[TBL] [Abstract][Full Text] [Related]
4. Decreased plasma exposure of clopidogrel active metabolite in rats after long-term treatment with clopidogrel.
Wang Y; Liu Y; Yao H; Chen X; Sun Y; Guo Y
Biopharm Drug Dispos; 2023 Apr; 44(2):129-136. PubMed ID: 36905582
[TBL] [Abstract][Full Text] [Related]
5. Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults.
Jiang XL; Samant S; Lewis JP; Horenstein RB; Shuldiner AR; Yerges-Armstrong LM; Peletier LA; Lesko LJ; Schmidt S
Eur J Pharm Sci; 2016 Jan; 82():64-78. PubMed ID: 26524713
[TBL] [Abstract][Full Text] [Related]
6. Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach.
Liu S; Wang Z; Tian X; Cai W
Front Pharmacol; 2020; 11():591854. PubMed ID: 33424602
[TBL] [Abstract][Full Text] [Related]
7. Type 2 diabetes mellitus decreases systemic exposure of clopidogrel active metabolite through upregulation of P-glycoprotein in rats.
Yao H; Gu J; Shan Y; Wang Y; Chen X; Sun D; Guo Y
Biochem Pharmacol; 2020 Oct; 180():114142. PubMed ID: 32653591
[TBL] [Abstract][Full Text] [Related]
8. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D
Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027
[TBL] [Abstract][Full Text] [Related]
9. Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention.
Saiz-Rodríguez M; Belmonte C; Caniego JL; Koller D; Zubiaur P; Bárcena E; Romero-Palacián D; Eugene AR; Ochoa D; Abad-Santos F
Clin Ther; 2019 Jun; 41(6):1199-1212.e2. PubMed ID: 31128980
[TBL] [Abstract][Full Text] [Related]
10. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
[TBL] [Abstract][Full Text] [Related]
11. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen.
Loisios-Konstantinidis I; Cristofoletti R; Jamei M; Turner D; Dressman J
Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33147873
[TBL] [Abstract][Full Text] [Related]
12. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
Frelinger AL; Bhatt DL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Lampa M; Brooks JK; Barnard MR; Michelson AD
J Am Coll Cardiol; 2013 Feb; 61(8):872-9. PubMed ID: 23333143
[TBL] [Abstract][Full Text] [Related]
13. Clopidogrel utilization in patients with coronary artery disease and diabetes mellitus: should we determine CYP2C19*2 genotype?
Chouchene S; Dabboubi R; Raddaoui H; Abroug H; Ben Hamda K; Hadj Fredj S; Abderrazak F; Gaaloul M; Rezek M; Neffeti F; Hellara I; Sassi M; Khefacha L; Sriha A; Nouira S; Najjar MF; Maatouk F; Messaoud T; Hassine M
Eur J Clin Pharmacol; 2018 Dec; 74(12):1567-1574. PubMed ID: 30073432
[TBL] [Abstract][Full Text] [Related]
14. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
Braun OÖ; Angiolillo DJ; Ferreiro JL; Jakubowski JA; Winters KJ; Effron MB; Duvvuru S; Costigan TM; Sundseth S; Walker JR; Saucedo JF; Kleiman NS; Varenhorst C
Thromb Haemost; 2013 Dec; 110(6):1223-31. PubMed ID: 24009042
[TBL] [Abstract][Full Text] [Related]
15. Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics.
Djebli N; Fabre D; Boulenc X; Fabre G; Sultan E; Hurbin F
Drug Metab Dispos; 2015 Apr; 43(4):510-22. PubMed ID: 25609219
[TBL] [Abstract][Full Text] [Related]
16. Impact of genetic variants of selected cytochrome P450 isoenzymes on pharmacokinetics and pharmacodynamics of clopidogrel in patients co-treated with atorvastatin or rosuvastatin.
Karaźniewicz-Łada M; Krzyżańska D; Danielak D; Rzeźniczak J; Główka F; Słomczyński M; Burchardt P
Eur J Clin Pharmacol; 2020 Mar; 76(3):419-430. PubMed ID: 31897532
[TBL] [Abstract][Full Text] [Related]
17. CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel.
Pedersen RS; Nielsen F; Stage TB; Vinholt PJ; el Achwah AB; Damkier P; Brosen K
Clin Exp Pharmacol Physiol; 2014 Nov; 41(11):870-8. PubMed ID: 25115434
[TBL] [Abstract][Full Text] [Related]
18. Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial.
Carreras ET; Hochholzer W; Frelinger AL; Nordio F; O'Donoghue ML; Wiviott SD; Angiolillo DJ; Michelson AD; Sabatine MS; Mega JL
Thromb Haemost; 2016 Jul; 116(1):69-77. PubMed ID: 27009617
[TBL] [Abstract][Full Text] [Related]
19. A physiologically based pharmacokinetic model of clopidogrel in populations of European and Japanese ancestry: An evaluation of CYP2C19 activity.
Duong JK; Nand RA; Patel A; Della Pasqua O; Gross AS
Pharmacol Res Perspect; 2022 Apr; 10(2):e00946. PubMed ID: 35307978
[TBL] [Abstract][Full Text] [Related]
20. Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug-Drug-Gene Interaction Predictions.
Loer HLH; Türk D; Gómez-Mantilla JD; Selzer D; Lehr T
Pharmaceutics; 2022 Apr; 14(5):. PubMed ID: 35631502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
